Antihyperlipemic and antihypertensive effects of Spirulina maxima in an open sample of Mexican population: a preliminary report

Patricia V Torres-Duran, Aldo Ferreira-Hermosillo, Marco A Juarez-Oropeza, Patricia V Torres-Duran, Aldo Ferreira-Hermosillo, Marco A Juarez-Oropeza

Abstract

Background: Spirulina maxima is a filamentous cyanobacterium used as food supplement because of its high nutrient contents. It has been experimentally proven, in vivo and in vitro that posses several pharmacological properties. The purpose of this study was to evaluate the effects of Spirulina maxima orally supplied (4.5 g/day, for 6 weeks) to a sample of 36 subjects (16 men and 20 women, with ages between 18-65 years) on serum lipids, glucose, aminotransferases and on blood pressure. The volunteers did not modify their dietary habits or lifestyle during the whole experimental period. From each subject, a sample of blood was drawn in fasting state of 12 hours to determi the plasma concentrations of glucose, triacylglycerols (TAG), total cholesterol (TC), cholesterol associated to high density lipoprotein (HDL-C) and aspartate aminotransferase (AST). Anthropometric measurements including systolic (SYST-P) and diastolic (DIAST-P) blood pressure, height, weight and Body Mass Index (BMI) were also recorded.

Results: Comparing initial and final data, the results showed that there were no significant changes in the values of glucose and AST, but significant differences in TAG, TC, and HDL-C, were observed: TAG 233.7 +/- 177.8 vs. 167.7 +/- 100.7 mg/dL (p < 0.001), TC 181.7 +/- 37.5 vs. 163.5 +/- 34.4 mg/dL (p < 0.001), C-HDL 43.5 +/- 14.4 vs. 50 +/- 18.8 mg/dL (p < 0.01). The univariated analysis showed that the changes in the HDL-C and TC concentrations were dependent on TAG concentration (p = 0.247 and p = 0.108, respectively); nevertheless the calculated values for cholesterol associated to low density lipoprotein (LDL-C) were significantly reduced by the Spirulina maxima treatment but independently of the TAG changes. In addition, significant differences were found comparing initial and final SYST-P and DIAST-P blood pressure in both male and female: SYST-P male 121 +/- 9 vs. 111 +/- 8 mm Hg (p < 0.01), DIAST-P male 85 +/- 6.5 vs. 77 +/- 9 mm Hg (p < 0.01); SYST-P female 120 +/- 9.5 vs. 109 +/- 11 mm Hg (p < 0.002), DIAST-P female 85 +/- 11 vs. 79 +/- 7.5 mm Hg (p < 0.03).

Conclusion: The Spirulina maxima showed a hypolipemic effect, especially on the TAG and the LDL-C concentrations but indirectly on TC and HDL-C values. It also reduces systolic and diastolic blood pressure.

References

    1. Crews DE. Senescence, aging, and disease. J Physiol Anthropol. 2007;26:365–372. doi: 10.2114/jpa2.26.365.
    1. Statistic, Geography and Informatics' National Institute (INEGI)
    1. Garcia-Garcia G, Aviles-Gomez R, Luquin-Arellano VH, Padilla-Ochoa R, Lepe-Murillo L, Ibarra-Hernandez M, Briseño-Renteria G. Cardiovascular risk factors in the Mexican population. Ren Fail. 2006;28:677–687. doi: 10.1080/08860220600936096.
    1. Comuzzie AG, Mitchell BD, Cole S, Martin LJ, Hsueh WC, Rainwater DL, Almasy L, Stern MP, Hixson J, MacCluer JW, Blangero J. The genetics of obesity in Mexican Americans: the evidence from genome scanning effects in the San Antonio family heart study. Hum Biol. 2003;75:635–646. doi: 10.1353/hub.2003.0073.
    1. Mitchell BD, Almasy LA, Rainwater DL, Schneider JL, Blangero J, Stern MP, MacCluer JW. Diabetes and hypertension in Mexican American families: relation to cardiovascular risk. Am J Epidemiol. 1999;149:1047–1056.
    1. Mitchell BD, Kammerer CM, Blangero J, Mahaney MC, Rainwater DL, Dyke B, Hixson JE, Henkel RD, Sharp RM, Comuzzie AG, VandeBerg JL, Stern MP, MacCluer JW. Genetic and environmental contributions to cardiovascular risk factors in Mexican Americans. The San Antonio Family Heart Study. Circulation. 1999;94:2159–2170.
    1. Gonzalez C, Stern MP, Gonzalez E, Rivera D, Simon J, Islas S, Haffner S. The Mexico City Diabetes Study: a population based approach to the study of genetic and environmental interactions in the pathogenesis of obesity and diabetes. Nutr Rev. 1999;57:S71–S76.
    1. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic Acid: pharmacological effects and mechanism of action. Annu Rev Pharmacol Toxicol. 2008.
    1. Frisinghelli A, Mafrici A. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review. Clin Drug Investig. 2007;27:591–604. doi: 10.2165/00044011-200727090-00001.
    1. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007;298:786–798. doi: 10.1001/jama.298.7.786.
    1. Wiklund O, Håversen L, Pettersson C, Hultén LM. How can we prevent cardiovascular disease in diabetes. J Intern Med. 2007;262:199–207. doi: 10.1111/j.1365-2796.2007.01828.x.
    1. Laclaustra M, Frangi AF, Casasnovas JA, Cia P. Association of endothelial function and vascular data with LDL-c and HDL-c in a homogeneous population of middle-aged, healthy military men: Evidence for a critical role of optimal lipid levels. Int J Cardiol. 2007
    1. Gadi R, Samaha FF. Dyslipidemia in type 2 diabetes mellitus. Curr Diab Rep. 2007;7:228–234. doi: 10.1007/s11892-007-0036-0.
    1. Ciferri O. Spirulina, the edible microorganism. Microbiol Rev. 1983;47:551–578.
    1. Khan Z, Bhadouria P, Bisen PS. Nutritional and therapeutic potential of Spirulina. Curr Pharm Biotechnol. 2005;6:373–379. doi: 10.2174/138920105774370607.
    1. Belay A, Kato T, Ota Y. Spirulina (Arthrospira): potencial application as an animal feed supplement. J Appl Phycol. 1996;8:303–311. doi: 10.1007/BF02178573.
    1. Chamorro G, Salazar M, Favila L, Bourges H. Pharmacology and toxicology of Spirulina alga. Rev Invest Clin. 1996;48:389–399.
    1. Ayehunie S, Belay A, Baba TW, Ruprecht RM. Inhibition of HIV-1 replication by an aqueous extract of Spirulina platensis (Arthrospira platensis) J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:7–12.
    1. Hayashi K, Hayashi T, Kojima I. A natural sulfated polysaccharide, calcium spirulan, isolated from Spirulina platensis: in vitro and ex vivo evaluation of anti-herpes simplex virus and anti-human immunodeficiency virus activities. AIDS Res Hum Retroviruses. 1996;12:1463–1471.
    1. Kapoor R, Metha U. Supplementary effect of Spirulina on hematological status of rats during pregnancy and lactation. Plant Foods Hum Nutr. 1998;52:315–324. doi: 10.1023/A:1008027408919.
    1. Premkumar K, Abraham SK, Santhiya ST, Ramesh A. Protective effect of Spirulina fusiformis on chemical-induced genotoxicity in mice. Fitoterapia. 2004;75:24–31. doi: 10.1016/j.fitote.2003.07.008.
    1. Torres-Duran PV, Miranda-Zamora R, Paredes-Carbajal MC, Mascher D, Diaz-Zagoya JC, Juarez-Oropeza MA. Spirulina maxima prevents induction of fatty liver by carbon tetrachloride in the rat. Biochem Mol Bio Int. 1998;44:768–793.
    1. Vadiraja HB, Gaikwad NW, Madyashta KM. Hepatoprotective effect of C-phycocyanin: protection for carbon tetrachloride and R-(+)-pulegone-mediated. Biochem Biophys Res Commun. 1998;249:428–431. doi: 10.1006/bbrc.1998.9149.
    1. Torres-Duran PV, Paredes-Carbajal MC, Mascher D, Zamora-Gonzalez J, Diaz-Zagoya JC, Juarez-Oropeza MA. Protective effects of Arthrospira maxima on fatty acid composition in fatty liver. Arch Med Res. 2006;37:479–483. doi: 10.1016/j.arcmed.2005.08.005.
    1. Kato T, Takemoto K. Effects of Spirulina on hypercholesterolemia and fatty liver in rats. Japan Nutr Foods Assoc J. 1984;37:321.
    1. Parikh P, Mani U, Iver U. Role of Spirulina in the control of glicemia and lipidemia in type 2 Diabetes Mellitus. J Med Food. 2001;4:193–199. doi: 10.1089/10966200152744463.
    1. Mazo VK, Gmoshinskñ IV, Zilova IS. Microalgae Spirulina in human nutrition. Vopr Pitan. 2004;73:45–53.
    1. Nayaka N, Homma Y, Goto Y. Cholesterol lowering effect of Spirulina. Nutr Rep Int. 1988;37:1329–1337.
    1. Ble-Castillo JL, Rodriguez-Hernandez A, Miranda-Zamora R, Juarez-Oropeza MA, Diaz-Zagoya JC. Arthrospira maxima prevents the acute fatty liver induced by the administration of simvastatin, ethanol and a hypercholesterolemic diet to mice. Life Sci. 2002;70:2665–2673. doi: 10.1016/S0024-3205(02)01512-6.
    1. Iwata K, Inayama T, Kato T. Effects of Spirulina platensis on plasma lipoprotein lipase activity in fructose-induced hyperlipidemic rats. J Nutr Sci Vitaminol. 1990;36:165–171.
    1. Mascher D, Paredes-Carbajal MC, Torres-Duran PV, Zamora-Gonzalez J, Diaz-Zagoya JC, Juarez-Oropeza MA. Ethanolic extract of Spirulina maxima alters the vasomotor reactivity of aortic rings from obese rats. Arch Med Res. 2006;37:50–57. doi: 10.1016/j.arcmed.2005.04.004.
    1. Paredes-Carabajal MC, Torres-Duran PV, Diaz-Xagoya JC, Mascher D, Juarez-Oropeza MA. Effects of dietary Spirulina maxima on endothelium dependent vasomotor responses of rat aortic rings. Life Sci. 1997;61:211–219. doi: 10.1016/S0024-3205(97)00715-7.
    1. Paredes-Carbajal MC, Torres-Duran PV, Diaz-Zagoya JC, Mascher D, Juarez-Oropeza MA. Effects of dietary Spirulina maxima on vasomotor aorta ring from rats fed a fructose-rich diet. Nutr Res. 1997;18:1769–1782. doi: 10.1016/S0271-5317(98)00140-7.
    1. Samuels R, Mani UV, Nayak US. Hypocholesterolemic effect of Spirulina in patients with hyperlipidemic nephrotic syndrome. J Med Food. 2002;5:91–96. doi: 10.1089/109662002760178177.
    1. Aguilar-Salinas CA, Olaniz G, Valles V, Rios-Torres JM, Gomez-Perez FJ, Rull JA, Rojas R, Franco A, Sepulveda J. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42:1298–1307.
    1. Olaiz-Fernandez G, Rivera-Dommarco J, Shamah-Levy T, Rojas R, Villalpando-Hernandez S, Hernandez-Avila M, Sepulveda-Amor J, (Ed) Mexican National Health and Nutrition Survey 2006. Cuernavaca, Mexico: National Public Health Institute; 2006.
    1. Stern MP, Williams K, Hunt KJ. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl. 2005;6:3–6. doi: 10.1016/j.atherosclerosissup.2005.02.002.
    1. Hayden MR. Atherogenic dyslipidemia. J Cardiometab Syndr. 2006;1:166–167.
    1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, Jones DW, Materson BJ, Oparil S, Wright JT, Jr, Roccella EJ, National Heart, Lung and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572. doi: 10.1001/jama.289.19.2560.
    1. Lima-Landman MT, Borges AC, Cysneiros RM, De Lima TC, Souccar C, Lapa AJ. Antihypertensive effect of a standardized aqueous extract of Cecropia glaziovii Sneth in rats: an in vivo approach to the hypotensive mechanism. Phytomedicine. 2007;14:314–320. doi: 10.1016/j.phymed.2007.03.003.
    1. Ojewole JA, Kamadyaapa DR, Gondwe MM, Moodley K, Musabayane CT. Cardiovascular effects of Persea Americana Mill (Lauraceae) (avocado) aqueous leaf extract in experimental animals. Cardiovasc J S Afr. 2007;18:69–76.
    1. Nagaoka S, Shimizu K, Kaneko H, Shibayama F, Morikawa K, Kanamaru Y, Otsuka A, Hirashi T, Kato T. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of Spirulina platensis concentrate in rats. J Nutr. 2005;135:2425–2430.
    1. Li-Kun H, Dong-Xia L, Lan X, Xiao-Jie G, Yasumasa K, Isao S, Hiromichi O. Isolation of pancreatic lipase activity-inhibitory component of Spirulina platensis and it reduce postprandial triacylglycerolemia. Yakugaku Zasshi. 2006;126:43–49. doi: 10.1248/yakushi.126.43.
    1. Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol. 2001;38:S3–S6.
    1. Hsiao G, Chou Po-Hsiu, Shen Ming-Yi, Chou Duen-Suey, Lin Chien-Huang, Sheu Joen-Rong. C-phycocyanin, a very potent and novel platetel aggregation inhibitor from Spirulina platensis. J Agric Food Chem. 2005;53:7734–7740. doi: 10.1021/jf051352y.
    1. Guan Y, Zhao HY, Ding XF, Zhu YY. Analysis of the contents of elements in Spirulina from different producing areas. Guang Pu Xue Yu Guang Pu Fen Xi. 2007;27:1029–1031.
    1. Berne C, Siewert-Delle A, URANUS study investigators Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;3:4–7.
    1. Rangineni V, Sharada D, Saxena S. Diuretic, hypotensive, and hypocholesterolemic effects of Eclipta alba in mild hypertensive subjects: a pilot study. J Med Food. 2007;10:143–148. doi: 10.1089/jmf.2006.0000.
    1. Herrera-Arellano A, Miranda-Sanchez J, Avila-Castro P, Herrera-Alvarez S, Jimenez-Ferrer JE, Zamilpa A, Roman-Ramos R, Ponce-Monter H, Tortoriello J. Clinical effects produced by a standardized herbal medicinal product of Hibiscus sabdariffa on patients with hypertension. A randomized, double-blind, lisinopril-controlled clinical trial. Planta Med. 2007;73:6–12. doi: 10.1055/s-2006-957065.
    1. Chamorro G, Salazar M, Salazar S. Estudio teratogenico de Spirulina en rata. Arch Latinoam Nutr. 1989;29:641–649.
    1. Chamorro GA, Herrera G, Salazar M, Salazar S, Ulloa V. Subchronic toxicity study in rats fed Spirulina. J Pharm Belg. 1988;24:104–106.
    1. Salazar M, Salazar S, Steele CE, Chamorro GA. Subchronic toxicity study in mice fed Spirulina maxima. J Ethnopharmacol. 1998;62:235–241. doi: 10.1016/S0378-8741(98)00080-4.
    1. Rubinstein A. National Cholesterol Education Program, second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation. 1995;91:908–909.
    1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486.
    1. De Long DM, De Long ER, Wood PD, Lippel K, Rifkind BM. A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The Lipid Research Clinics Prevalence Study. JAMA. 1986;256:2372–2377. doi: 10.1001/jama.256.17.2372.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir